Tulisokibart

Summary

Tulisokibart (CHEMBL5095370) is a phase-3 clinical-stage antibody; indicated across 3 conditions including crohn disease and ulcerative colitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095370
Name	Tulisokibart
Type	Antibody
Max phase	3

Also known as: PRA-023, PRA023, Tulisokibart, TULISOKIBART

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Crohn disease	3	MONDO:0005011	EFO:0000384
ulcerative colitis	3	MONDO:0005101	EFO:0000729
interstitial lung disease	1	MONDO:0015925	HP:0006515

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06651281	PHASE3	RECRUITING	Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn’s Disease or Ulcerative Colitis (MK-7240-011)
NCT05270668	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT06956235	PHASE2	ACTIVE_NOT_RECRUITING	Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT07133633	PHASE2	RECRUITING	A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07176390	PHASE2	RECRUITING	A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07486960	PHASE2	RECRUITING	Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT04996797	PHASE2	COMPLETED	A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
NCT05013905	PHASE2	COMPLETED	A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn’s Disease (MK-7240-006)
NCT04676178	PHASE1	COMPLETED	A Study of PRA023 in Healthy Volunteers
NCT06575595	PHASE1	COMPLETED	Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
NCT06829225	PHASE1	COMPLETED	Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).